Met-Hb and inflammation markers with tumescence local anaesthesia (TLA)

Met-Hb-concentration and inflammation markers in patients undergoing tumescence local anaesthesia (TLA) with supramaximal dosages of prilocaine

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN19821978

Enrollment

Registered

2008-03-20

Start date

2008-02-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tumescence local anaesthesia (TLA)/established anaesthesia techniques Signs and Symptoms Anaesthesia techniques

Interventions

As a standard procedure in our clinic, patients with dermatological operations will receive a TLA with more than 600 mg prilocaine. Seven blood samples (approximately 8 ml) will be taken 0, 1, 2, 4, 1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients (male/female) with operations which are performed in TLA with prilocaine 2. Age: 18 - 85 years 3. American Society of Anaesthesiologists (ASA) grade I - III 4. No allergy against prilocaine

Exclusion criteria

Exclusion criteria: 1. Allergy against prilocaine 2. Pregnancy 3. Patient denies operation in TLA

Design outcomes

Primary

Measure	Time frame
Met-Hb-concentration over the time, measured over 48 hours.	—

Secondary

Measure	Time frame
Elevation of inflammation markers, measured over 48 hours.	—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026